Nonexclusive transaction with Biocancer will allow both firms to co-market and contract services.

Averion and Biocancer, two clinical research organizations (CROs), will jointly market and contract complementary services to biotechnology, pharmaceutical, and medical device companies.


Biocancer is based in Brazil and focuses on oncology. “This agreement expands our reach to South America, providing us with access to leading clinical sites and large patient populations,” points out Philip Lavin, Ph.D., Averion’s CEO. “We plan to continue building on our international oncology CRO offering through strategic partnerships and acquisitions.”

Previous articleCephalon Purchases Muscle Relaxant for $100M
Next articleGene Logic Tasked with Repositioning Merck Serono Drugs